Selling, General, and Administrative Costs: Bausch Health Companies Inc. vs Wave Life Sciences Ltd.

SG&A Expenses: Bausch Health vs. Wave Life Sciences

__timestampBausch Health Companies Inc.Wave Life Sciences Ltd.
Wednesday, January 1, 201420263000002999000
Thursday, January 1, 2015268270000010393000
Friday, January 1, 2016281000000015994000
Sunday, January 1, 2017258200000026975000
Monday, January 1, 2018247300000039509000
Tuesday, January 1, 2019255400000048869000
Wednesday, January 1, 2020236700000042510000
Friday, January 1, 2021262400000046105000
Saturday, January 1, 2022262500000050513000
Sunday, January 1, 2023291700000051292000
Loading chart...

Cracking the code

A Tale of Two Companies: SG&A Expenses Over Time

In the world of corporate finance, Selling, General, and Administrative (SG&A) expenses are a critical measure of a company's operational efficiency. This chart compares the SG&A expenses of Bausch Health Companies Inc. and Wave Life Sciences Ltd. from 2014 to 2023. Bausch Health, a major player in the pharmaceutical industry, consistently reported SG&A expenses in the billions, peaking at approximately $2.9 billion in 2023. In contrast, Wave Life Sciences, a smaller biotech firm, saw its SG&A expenses grow from around $3 million in 2014 to over $51 million in 2023, marking a staggering increase of over 1,600%. This comparison highlights the scale and growth dynamics between a large established company and an emerging biotech firm. Understanding these trends provides valuable insights into how each company allocates resources to support their business operations and growth strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025